Pathological findings directing immunotherapy in renal cell carcinomas.
Immunotherapy
PD-1
PD-L1
nivolumab
renal cell carcinoma
Journal
Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
Tweetable abstract Immunotherapy options in RCC treatment are increasing day by day. In pursuit of this objective, we have explored the role of pathology throughout the process, from the development to the implementation of immunotherapy in this paper.
Identifiants
pubmed: 38214137
doi: 10.2217/imt-2023-0249
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM